#7

Klauber & Jackson Attorneys At Law Continental Plaza 411 Hackensack Avenue Hackensack, New Jersey 07601

TELEPHONE: (201) 487-5800

THE FIRM'S FACSIMILE TRANSMITTERS: (201) 343-1684 or (201) 343-7544

TO:	Exami	ner Marianne DiBrino	
FROM:	Marth	a Bussanich	
DATE:	Octobe	er 3, 2002	
PAGES TO F	OLLOW: 3		
Message:			
Dear Examine	er DiBrino:		
	ephone conversatio inary Amendment.		f mailing and the Marked-upVersion
Martha Bussa	nich		
File No.	1300-1-008	Fax Tel No.	703-746-5244
If you have any	questions regarding	compatibility, you may reach	h us at (201) 487-5800.

NOTE: The information contained in this facsimile message is attorney-client privileged and contains confident al information intended only for the use of the individual named above and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (201-487-5800) and return the original transmission to us by mail without making a copy.

EXPRESS POST OFFICE TO ADDRESSEE	EL 75A5215A2 US
ORIGIN (POSTAL USE ONLY) PO ZIP Codie Day (P.Ostivery Flat Rate Envolppe	OI DE REVERSE SIDE FOR S X SERVICE GUARANTEE AND LIMITS ON INSURANCE COVERAGE WAIVER OF BIGNATURE IPONISHE DAYS ACCURANT MENTANCE IS VOID IT WAIVEN
No Dollnory Account of Clark Initials Total Possing & Fees State Office Clark Initials Total Possing & Fees State Office Clark Initials State Office Clark Initial State Office Clark Initial State Office Clark Initial State Off	WAIVER OF BIGNATURE (Domestic Dayly: Additional meditional servance) and il weiver of elignature is reducated. Which fishway to be made without obtaining stocking of the second of objects appelled the property of the second of the second of the second objects of
FROM: PREASE PRINT PHONE: 201, 427-5000 -110-10-10-10-10-10-10-10-10-10-10-10-10	DOX POT PATENT APPLICATION ASSISTANT CONMISSIONER FOR PATENTS WASHINGTON, D.C., 20201
1009-1-008 (D. Jackson/Ts) FOR PICKUP OR TRACKING CALL 1-800	L 222-1811 WWW.usps.com 宝酮等

PCT/GB99/03747 1	.300-1-008_ DAJ/1s					
Serial No. File No. Tille ANTIBODY-SERUM PROT	יבוע עספטו אלי	a				
Tille ANT LOUD 1-32 RUM FROT	ETIL HIDKIDS					
In the Matter of the Application of Bryan John Smith						
The following was received in the U.S. F	Patent & Trademark Office on the date	F				
stamped hereon: VIA EXPRESS M&	IL_#EL 758521582 US	C 1.				
L	19/831676	5				
Transmittal Sheet/Cover Ltr. in dup	Extension of Time- 4	ICIT Rec'd PCT/PTO				
(X) Application For Palent	🔲 lesua Fee Transmittal	\ ;;				
Declaration	tad Mainlanance Fee	\				
Drawings	Appin. TM Registration	مــين ^ا				
S.E. Verified Statements	☐ 8 & 15 Declaration					
☐ Assignment	Renewal Application	*				
K Check for \$ 860.00	☐ Notice of Appeal	=<				
☐ Letter ☐ Missing Parts	☐ Brief ☐ Petition	5				
☐ Priority Document	☐ Power of Attorney	9				
🖄 Amendment 🔲 Response	XII copies of Intern'l Sear	rch				
PRELIMINARY Report;	Exam Report: Written Opin					

S. Z. William

DOCKETED CPI

1-308 10/3/02 -mo Attorney Docket No.: 1300-1-308

VERSION WITH MARKINGS TO SHOW CHANGES MADE

- 3. (Amended) A hybrid protein according to Claim 1 [or Claim 2] wherein each serum carrier protein is thyroxine-binding protein, transthyretin, al-acid glycoprotein, transferrin, fibrinogen or albumin or a fragment thereof.
- 4. (Amended) A hybrid protein according to Claim 1 [to Claim 3] wherein each antibocy fragment is a monovalent Fab fragment optionally containing one or more additional amino acids attached to the C-terminus of the CH1 domain.
- 6. (Amended) A hybrid protein according to Claim 1 [any one of the preceding claims] comprising one antigen-binding antibody fragment covalently linked to an albumin molecule of a fragment thereof.
- 10. (Amended) A hybrid protein according to Claim 8 [or Claim 9] wherein the bridging molecule is from around 10A to around 20A in length.
- 12. (Amended) A hybrid protein according to Claim 1 [any one of the preceding claims] covalently linked to one or more effector or reporter groups.
- 13. (Amended) A pharmaceutical composition comprising a hybrid protein according to Claim 1 [any one of the preceding claims] together with one or more pharmaceutically acceptable excipients, diluents or carriers.